Table 2.
Efficacy outcomes during maintenance treatment period
| CZP 400 mg Q2W/CZP 400 mg Q2W (n = 49) | CZP 200 mg Q2W/CZP 200 mg Q2W (n = 20) | CZP 200 mg Q2W/CZP 400 mg Q4W (n = 20) | CZP 200 mg Q2W combined (n = 40) | |
|---|---|---|---|---|
| PASI 75, n (%) | ||||
| Week 16 | 46 (93.9) | 17 (85.0) | 17 (85.0) | 34 (85.0) |
| Week 52 | 44 (89.8) | 18 (90.0) | 17 (85.0) | 35 (87.5) |
| PASI 90, n (%) | ||||
| Week 16 | 40 (81.6) | 12 (60.0) | 13 (65.0) | 25 (62.5) |
| Week 52 | 43 (87.8) | 15 (75.0) | 14 (70.0) | 29 (72.5) |
| PASI 100, n (%) | ||||
| Week 16 | 9 (18.4) | 6 (30.0) | 5 (25.0) | 11 (27.5) |
| Week 52 | 22 (44.9) | 4 (20.0) | 5 (25.0) | 9 (22.5) |
| PGA 0/1, n (%) | ||||
| Week 16 | 35 (71.4) | 11 (55.0) | 13 (65.0) | 24 (60.0) |
| Week 52 | 38 (77.6) | 15 (75.0) | 15 (75.0) | 30 (75.0) |
Responder rates are from the BM Full Analysis Set (IA definition) and summarised according to blinded maintenance treatment group. Missing values were imputed using NRI. Only two patients continued placebo treatment to week 52; therefore, placebo data are not shown. BM blinded maintenance, IA interim analysis, NRI non-responder imputation, PASI 75/90/100 at least 75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index, PGA Physician’s Global Assessment, Q2W every 2 weeks, Q4W every 4 weeks